Tuesday, November 12, 2019

WuXi AppTec Reports First Half 2019 Interim Results

Revenue Accelerated 33.7% Year-Over-Year to RMB 5,894 Million Gross Profit Up 30.0% Year-Over-Year to RMB 2,284 million1  Adjusted Non-IFRS Net...

WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections

SHANGHAI, 24 July, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) in Shanghai and active pharmaceutical ingredient (API) process R&D...

WuXi AppTec Named One of MIT Technology Review’s 50 Smartest Companies

  Shanghai, June 29, 2019 – WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been...

WuXi AppTec’s Enabling Capability Recognized by Partners and Philadelphia Authority at BIO 2019

By WuXi Content Team WuXi AppTec’s enabling capabilities and contribution to the development of life science were recognized by both its many partners and the City of Philadelphia at the BIO International...

Subscribe to our Newsletter



Twitter LinkedIn